TEVA 株価分析 — TEVA PHARMA INDUSTRIES LTD ADR (Healthcare >> Drug Manufacturers - Specialty & Generic)
TEVA に関するよくある質問
TEVAのPER(株価収益率)は?
TEVA PHARMA INDUSTRIES LTD ADR(TEVA)は現在PER 32.16倍で取引されています。
TEVAのROE(自己資本利益率)は?
TEVA PHARMA INDUSTRIES LTD ADRのROEは9.11%です。
TEVAの配当利回りは?
TEVA PHARMA INDUSTRIES LTD ADRの配当利回りは0.00%です。
TEVAの品質スコア(Quality Score)は?
当社のAIはTEVAの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
TEVAは今が買い時ですか?
当社AIのタイミングスコアは100点中64点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
TEVAはどのセクターに属しますか?
TEVA PHARMA INDUSTRIES LTD ADRはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます(NYSE市場)
TEVA AI Analysis Summary
Our AI summary for TEVA: TEVA PHARMA INDUSTRIES LTD ADR (NYSE), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 32.16, ROE of 9.11%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 64/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 35.01
Price
-0.40
(-1.13%)
Day Change
|
|
|---|
TEVA, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
2355
|
| Magic Formula Rank by ROE |
2355
|
| Magic Formula Rank by ROIC |
2435
|
| Price | 35.01 |
| PBV / Sector |
5.32 / 3.22
|
| Earning Per Share | 0.60 |
| PE / Sector |
32.16 / 29.79
|
| PEG or PE/Growth / Sector |
-1.37 / 0.13
|
| Average 1M Daily Value |
167.55 M
GREAT
|
| Average 1W Daily Value |
273.03 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:34 |
| Symbol | TEVA |
| Name | TEVA PHARMA INDUSTRIES LTD ADR |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NYSE |
| Listed Shares | 1,164.43 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 41,232.36 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 124 Dvora HaNevi?a St., Tel Aviv-Yafo, Israel, 6944020
Phone: 972 3 914 8213
Website: https://www.tevapharm.com
Employees: 31,173
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google